Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195011 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02195011 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 26 participants.
The verdict
NCT02195011, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of regorafenib, an antiangiogenic drug, when combined with radioembolization using SIR-Spheres® microspheres in the treatment of colorectal cancer (CRC) that has spread to the liver.
Interventions
- DRUG Regorafenib
- DEVICE SIR-Spheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195011
The ClinicalTrials.gov registry entry for NCT02195011 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regorafenib is the first listed.
NCT02195011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195011 about?
NCT02195011 is a clinical study titled "Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases". The purpose of this study is to determine the safety of regorafenib, an antiangiogenic drug, when combined with radioembolization using SIR-Spheres® microspheres in the treatment of colorectal cancer (CRC) that has spread to the liver.
What is the current status of trial NCT02195011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2014-07. Estimated completion is 2017-06-04.
What interventions are being tested in trial NCT02195011?
The interventions under investigation include: Regorafenib (DRUG), SIR-Spheres (DEVICE).
Who is sponsoring clinical trial NCT02195011?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.